OmniAb Inc

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. The firm’s platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OmniAb Inc reports robust Q4 earnings, poised for biotech innovation

OmniAb Inc delivered strong financial performance in Q4 2022, showcasing revenue growth and a healthy cash position. The company's focus on innovation, diverse platform, and strategic partnerships position them for continued success. While challenges like partner retention and funding concerns exist, OmniAb's strengths in technology and commitment to discovery present significant opportunities for growth.
With a strong capital position, OmniAb is well-equipped to navigate challenges and capitalize on opportunities in the biotech space. The company's emphasis on internal technology development, strategic acquisitions, and employee engagement underscores a proactive approach to sustaining leadership in antibody discovery. By leveraging their strengths and seizing opportunities, OmniAb is poised for future growth and market differentiation.
OmniAb's commitment to innovation, diverse platform, and strong capital position set the stage for continued success in antibody discovery. Challenges such as partner retention and funding uncertainties require strategic navigation. By focusing on technology development, strategic partnerships, and employee motivation, OmniAb can overcome challenges and leverage opportunities for sustained growth and market leadership.

OmniAb Inc reports strong revenue growth and strategic milestones

OmniAb Inc's Q1 2023 performance reflects robust revenue growth, strategic milestones, and a commitment to innovation in antibody discovery and development.
The company's strengths lie in its diverse host systems, proprietary platforms, strong partnerships, and scalable business model, positioning it for continued success.
While facing challenges in operational clarity and industry funding cycles, OmniAb has opportunities to drive growth through M&A, investments, and engagement with stakeholders.

OmniAb Inc reports revenue growth and strategic partnerships in Q2

OmniAb Inc's Q2 performance reflects revenue growth from new partnerships and a strong financial position with significant cash reserves
The company's technology strengths lie in its diverse host systems, successful partnerships, and innovative AI-driven tools for antibody discovery
While facing challenges like market headwinds and attrition rates, OmniAb sees opportunities in academic partnerships, regulatory changes, and ion channel programs

OmniAb Inc reports growth in partnerships but faces revenue challenges

OmniAb Inc showed growth in partnerships and programs but faced challenges with revenue and expenses in 2023.
The company's strengths lie in successful product launches, new partnerships, and a strategic focus on revenue growth sources.
Opportunities for growth include advancements in programs, lower cash use projections, and investments in new technologies.
Addressing challenges like revenue fluctuations and market uncertainties will be crucial for OmniAb's future success.

OmniAb Inc reports revenue growth and pipeline strength in Q1

OmniAb Inc's Q1 2024 performance showcased revenue growth and strong partnership developments, despite a net loss.
The company's pipeline strength, progress in clinical trials, and financial stability are key strengths driving future prospects.
Challenges include managing expenses, partner decisions impacting programs, and maintaining cash usage levels for growth initiatives.
Opportunities lie in expanding partnerships, advancing pre-clinical programs, exploring new collaborations, and leveraging positive market outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (Nasdaq: OABI) held its first Research & Technology virtual event earlier today, during which members of the management team reviewed the Company's technology offerings and highlighted the launch of OmnidAb, the industry's first and only transgenic chicken producing single domain antibodies (sdAbs). The archived webcast and speaker slides will be available on the Investors portion of OmniAb's website. “Since the completion of the transaction.

OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates. “Our business momentum has continued with the recent addition of three new partners including another global pharma company. Despite macroeconomic conditions, OmniAb's partner portfolio has continued to grow this year with a total of 314 active partner programs as of quarter-end, up from 291.

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. “We are delighted Steve has agreed to join the OmniAb Board of Directors.

OmniAb Appoints Steve Love to its Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:00 a.m. Eastern time. The two-hour event will include an update on the company's technology offerings, a review of third quarter financial results, which will be announced earlier that morning, and a Q&A session. The agenda for the event is as follows: Business Overview and Updates – Matt Foehr, Chief Execu.

OmniAb Announces Agenda for its Research & Technology Virtual Event

Archer Aviation

Digital Turbine

Cambium Networks Corp

Planet Labs

Taboola

Telos

Generally speaking, you get what you pay for, which should be a warning for speculating on low-priced securities, even if they're labeled the best cheap stocks under $5. Yes, I'm already working against my own thesis.

7 of the Best Cheap Stocks to Buy Under $5 in October 2023

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. Eastern time. The event is expected to last approximately two hours and will include a review of the company's latest technology offerings and financial results for the three and nine months ended September 30, 2023, which will be announced earlier that morning. Matt Foehr, Chief Executive Officer, will be joined.

OmniAb to Hold Research & Technology Virtual Event on November 9

OmniAb is a long-term growth story. The company's Q2 earnings call reported nice growth in its projects and partners. As a newly formed company with lumpy revenues and limited liquidity, OmniAb still has work to do to support a bull thesis.

OmniAb: Hold For Growth

OmniAb, Inc. (NASDAQ:OABI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Kurt Gustafson - CFO Matthew Foehr - President, CEO Conference Call Participants Puneet Souda - Leerink Partners Robyn Karnauskas - Truist Securities Stephen Willey - Stifel Jack Siedow - Craig-Hallum Chad Wiatrowski - TD Cowen Brandon Carney - B.Riley Operator Good afternoon, and welcome to OmniAb, Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

OmniAb, Inc. (OABI) Q2 2023 Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates. “Our business continued to grow and perform well during the second quarter with advancements in business development and progress across partner programs. The addition of four new partners during the quarter, including Merck & Co. and Neurocrine Biosciences, highlights the relevance and robustn.

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #OABI--OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week. The Board of Directors and leadership of OmniAb extend their deepest condolences to those who loved and cared for Sunil and express their gratitude for Sunil's many contributions to OmniAb. Sunil Patel was appointed to OmniAb's Board in November 2022 when OmniAb was spun-out of Ligand Pharmaceuticals as an independent, publicly-traded company, and previously serve.

OmniAb Announces the Passing of Director Sunil Patel

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 10, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information   What: OmniAb conference call to discuss financial results and business updates   Date: Thursday, August 10, 2023   Time: 4:30 p.m. Eastern time   Conferenc.

OmniAb to Report Second Quarter 2023 Financial Results on August 10

Shares of antibody discovery platform concern OmniAb have recovered marginally from their SPAC-birthed debut, when they were down 61% in their first day of regular-way trading. With three approved antibody therapies and 24 in the clinic, the company's approach to discovery has been validated. With an average program value of ~$1.5 million (net of cash) in a space that currently has 51 blockbuster therapies, the recent insider buying merited a deeper dive.

OmniAb: Plenty Of Potential

Aeva Technologies Inc

iQIYI

Lovesac Company

Mersana Therapeutics

Plug Power

Rush Street Interactive

In order for a stock to provide 200% returns it needs to at least triple in price. That's the kind of shares we'll be discussing below.

7 Stocks to Buy for 200% Returns This Year

Fathom Holdings

Magic Software Enterprises

VAALCO Energy

Prenetics Global Ltd

If Warren Buffett was your financial advisor, he might steer you toward reliable blue-chip investments, not wildly speculative stocks to buy now. Put another way, you're probably not going to find these enterprises listed among the holdings of Berkshire Hathaway (NYSE: BRK-B ).

7 Stocks to Buy for Their Massive Upside Potential

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) announced the launch of OmniDeep™ at the 19th Annual PEGS Boston Conference and Expo: The Essential Protein Engineering & Cell Therapy Summit. The Company introduced elements of its OmniDeep platform at 1:10 p.m. Eastern time today in a presentation by Bob Chen, Ph.D., OmniAb's Senior Director, Systems Engineering. OmniDeep is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniA.

OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo

Esperion Therapeutics

Getaround Inc

Globalstar

Sonder Holdings

Latham Group

Penny stocks to buy according to 7 insiders in May 2023. The post 7 Hot Penny Stocks To Buy In May According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks To Buy In May According To Insiders

Young though it is, OmniAb's business has sterling growth metrics. Discouragingly, OmniAb's financial profile is still in a protean phase of development.

OmniAb: 6 Months In And Going Strong

OmniAb, Inc. (NASDAQ:OABI ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Kurt Gustafson - CFO Matt Foehr - President, CEO Conference Call Participants Nishant Gandhi - Truist Securities Stephen Willey - Stifel Joe Pantginis - H.C. Wainwright Puneet Souda - SVB Securities Steven Mah - TD Securities Matt Hewitt - Craig-Hallum Capital Group Operator Good morning, and welcome to the OmniAb Inc.'s First Quarter 2023 Financial Results and Business Update Conference Call.

OmniAb, Inc. (OABI) Q1 2023 Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates. “Our first quarter performance is a strong start to the year. We reached 301 active programs, with 27 in clinical development or approved for commercialization as our growing portfolio of partner programs continued to advance,” said Matt Foehr, Chief Executive Officer of OmniAb, Inc. “Innovating our techn.

OmniAb Reports First Quarter 2023 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call that same day beginning at 8:30 a.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss financial results and business updates       Date:   Thursday, May 11, 2023       Time:   8:30 a.m. Eastern time       Confer.

OmniAb to Report First Quarter 2023 Financial Results on May 11

Point Biopharma Global

Verrica Pharmaceuticals Inc

Adicet Bio, Inc.

AC Immune

Altimmune

CorMedix

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just introduce health-related products directly to the market.

7 Biotech Stocks With Huge Return Potential for Long-Term Investors

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five upcoming investor conferences in May. H.C. Wainwright BioConnect Investor Conference at NASDAQ, May 2, 2023 at Nasdaq World Headquarters, New York City. Management will be participating in a fireside chat on Tuesday, May 2nd at 9:30 a.m. Eastern time and will be hosting one-on-one meetings with investors. Inaugural E.F. Hutton Global Conference, May 10-11, 2023 at The P.

OmniAb to Participate in Upcoming Investor Conferences in May

OmniAb, Inc. (NASDAQ:OABI ) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Kurt Gustafson - CFO Matt Foehr - President and CEO Conference Call Participants Nishant Gandhi - Truist Securities Joseph Pantginis - H.C. Wainwright & Co. Steven Mah - TD Cowen Puneet Souda - SVB Securities Yuan Zhi - B.

OmniAb, Inc. (OABI) Q4 2022 Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates. “Following the closing of the spin-off and business combination transactions last November, OmniAb is well-positioned for continued growth by offering cutting-edge antibody discovery platforms and complementary technologies,” said Matt Foehr, Chief Executive Officer of OmniAb.

OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Agios Pharmaceuticals

Veracyte

Verona Pharma

Janux Therapeutics

Sol-Gel Technologies

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.

News for OmniAb Inc Stock (OABI)